Roivant Sciences (NASDAQ:ROIV) Stock Rating Upgraded by Cantor Fitzgerald

Roivant Sciences (NASDAQ:ROIV) was upgraded by investment analysts at Cantor Fitzgerald to a “strong-buy” rating in a research report issued to clients and investors on Tuesday,Zacks.com reports.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $18.00 price target on shares of Roivant Sciences in a research report on Tuesday, February 11th. One investment analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Roivant Sciences has an average rating of “Buy” and an average price target of $18.08.

Roivant Sciences Stock Up 3.7 %

Roivant Sciences stock opened at $10.70 on Tuesday. The business has a fifty day moving average of $11.01 and a two-hundred day moving average of $11.57. The firm has a market cap of $7.63 billion, a P/E ratio of -71.33 and a beta of 1.25. Roivant Sciences has a twelve month low of $9.76 and a twelve month high of $13.06.

Roivant Sciences (NASDAQ:ROIV) last issued its quarterly earnings results on Monday, February 10th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.04. Roivant Sciences had a negative return on equity of 14.05% and a negative net margin of 119.54%. Equities analysts expect that Roivant Sciences will post -0.92 earnings per share for the current year.

Insider Activity at Roivant Sciences

In other news, Director Sciences Ltd. Roivant bought 16,845,010 shares of the business’s stock in a transaction that occurred on Monday, January 13th. The shares were purchased at an average cost of $20.00 per share, with a total value of $336,900,200.00. Following the transaction, the director now directly owns 96,650,341 shares in the company, valued at approximately $1,933,006,820. The trade was a 21.11 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, COO Eric Venker sold 100,000 shares of the company’s stock in a transaction on Friday, December 20th. The shares were sold at an average price of $11.49, for a total value of $1,149,000.00. Following the completion of the transaction, the chief operating officer now directly owns 595,580 shares in the company, valued at approximately $6,843,214.20. The trade was a 14.38 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 2,388,170 shares of company stock valued at $27,612,299 in the last ninety days. Company insiders own 7.90% of the company’s stock.

Institutional Investors Weigh In On Roivant Sciences

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. FMR LLC grew its position in Roivant Sciences by 0.3% during the 4th quarter. FMR LLC now owns 49,301,583 shares of the company’s stock worth $583,238,000 after purchasing an additional 156,527 shares during the period. Vanguard Group Inc. grew its position in Roivant Sciences by 5.8% during the 4th quarter. Vanguard Group Inc. now owns 44,087,287 shares of the company’s stock worth $521,553,000 after purchasing an additional 2,404,232 shares during the period. State Street Corp grew its position in Roivant Sciences by 6.1% during the 3rd quarter. State Street Corp now owns 19,561,249 shares of the company’s stock worth $225,737,000 after purchasing an additional 1,118,561 shares during the period. Patient Square Capital LP grew its position in Roivant Sciences by 2.1% during the 4th quarter. Patient Square Capital LP now owns 12,480,000 shares of the company’s stock worth $147,638,000 after purchasing an additional 251,535 shares during the period. Finally, Two Seas Capital LP grew its position in Roivant Sciences by 4.6% during the 4th quarter. Two Seas Capital LP now owns 10,167,807 shares of the company’s stock worth $120,285,000 after purchasing an additional 442,914 shares during the period. 64.76% of the stock is owned by institutional investors and hedge funds.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.